Recovery of Diminished Mealtime-Associated Anticipatory Behavior by Aniracetam in Aged Rats

Tanaka, Yushiro

doi:10.1016/s0091-3057(00)00288-4

Cited by 11 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the mechanisms of this phenomenon remain to be fully elucidated. A few studies on the food entrainment in aged rodents produced conflicting results, some suggesting that this rhythm deteriorates with age [21], [22]. However, others did not confirm this conclusion [23].…”

Section: Discussionmentioning

confidence: 99%

Cognitive Aging in Zebrafish

et al. 2006

View full text Add to dashboard Cite

BackgroundAge-related impairments in cognitive functions represent a growing clinical and social issue. Genetic and behavioral characterization of animal models can provide critical information on the intrinsic and environmental factors that determine the deterioration or preservation of cognitive abilities throughout life.Methodology/Principal FindingsBehavior of wild-type, mutant and gamma-irradiated zebrafish (Danio rerio) was documented using image-analysis technique. Conditioned responses to spatial, visual and temporal cues were investigated in young, middle-aged and old animals. The results demonstrate that zebrafish aging is associated with changes in cognitive responses to emotionally positive and negative experiences, reduced generalization of adaptive associations, increased stereotypic and reduced exploratory behavior and altered temporal entrainment. Genetic upregulation of cholinergic transmission attenuates cognitive decline in middle-aged achesb55/+ mutants, compared to wild-type siblings. In contrast, the genotoxic stress of gamma-irradiation accelerates the onset of cognitive impairment in young zebrafish.Conclusions/SignificanceThese findings would allow the use of powerful molecular biological resources accumulated in the zebrafish field to address the mechanisms of cognitive senescence, and promote the search for therapeutic strategies which may attenuate age-related cognitive decline.

show abstract

Section: Discussionmentioning

confidence: 99%

Cognitive Aging in Zebrafish

et al. 2006

View full text Add to dashboard Cite

show abstract

“…FAA was impaired in 24-month-old rats and MK-801-treated rats. Daily injections of bifemelane or aniracetam (an experimental drug with potential cognition-enhancing effects) for six successive days signifi cantly attenuated the impairment of FAA in a dose-dependent manner (Shibata et al 1995 ;Tanaka et al 2000 ). These results suggest that bifemelane and aniracetam enhance learning and memory performance, such as spatial and temporal perception.…”

Section: Role Of Aging In the Feomentioning

confidence: 83%

Circadian Rhythm and Food/Nutrition

Tahara

Shibata

2014

Mechanisms of Circadian Systems in Animals and Their Clinical Relevance

View full text Add to dashboard Cite

Scheduled food access during the daytime for nocturnal mice or rats entrains the food-entrainable oscillator (FEO) in the brain and the food-entrainable peripheral oscillator (FEPO) in the peripheral tissues. FEO and FEPO are not regulated by the central clock, which is in the suprachiasmatic nucleus. FEO produces food anticipatory activity (FAA) 2-3 h before the scheduled feeding time initiates. FEPO produces entrainment in the rhythm of peripheral clock gene expression and in the rhythm of food-metabolic functions in peripheral organs. At present, the mechanisms of the FEO and FEPO are not completely understood, despite many studies that have been performed in this fi eld. In addition, circadian clocks affect metabolism of nutrition (absorption, distribution, metabolism, excretion). In this review, we describe and review the characteristics and biological implications of FEO and FEPO and the mechanism of metabolism of nutrition with day-night differences. We call this relationship between nutrition and chronobiology "Chrono-nutrition," which is an important study fi eld to understand how our body clocks contribute to our health throughout the day.

show abstract

“…Successive free feeding for about 2 months greatly diminished the performance of aged rats, as revealed by a reduction in lever pressing with low choice accuracy, high choice omission and slow response speed. By chronic administration to these animals aniracetam, 10 and 30 mg/kg p.o., once daily for 14 consecutive days, dose-dependently restored the satiation-induced poor task performance, especially the rate of lever pressing, choice accuracy and no choice, without altering task-associated motor activity, premature response (impulsivity) or body weight, suggesting no change in motor ability, food motivation or reference memory (89). The authors indicate that satiation satisfies the appetite of rats and reduces their motivation to perform and to attain the operant task.…”

Section: Poor Performancementioning

confidence: 87%

“…Anticipatory behavior emerged on day 7 in young rats when the animals were fed only at a fixed time for 6 days, while in the aging rats the activity was diminished. By repeated administration (once daily for 7 days) aniracetam, 30 or 100 mg/kg p.o., restored the diminished anticipatory behavior in aging rats in a dose-dependent manner, as did physostigmine, 0.1 mg/kg s.c., an acetylcholinesterase inhibitor (89). The ameliorating effects of aniracetam were independent of a change in appetite, motor ability or circadian motor activity rhythm.…”

Section: Disturbed Temporal Regulationmentioning

confidence: 88%

“…Recent preclinical studies identified novel beneficial properties of aniracetam, that are related to functional recovery in various animal models of cerebral dysfunctional disorders. Those include hypoattention, hypovigilance-arousal (52,56,57), impulsive behavior (55), hyperactivity, fear and anxiety (54), depression (60), suppressed REM sleep (31), motivational drive reduction (53), chronobiological impairment (89), and bladder overactivity (51).…”

Section: Potential Clinical Indicationsmentioning

confidence: 99%

See 1 more Smart Citation

Aniracetam: Its Novel Therapeutic Potential in Cerebral Dysfunctional Disorders Based on Recent Pharmacological Discoveries

Nakamura¹

2002

CNS Drug Reviews

View full text Add to dashboard Cite

Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease. New discoveries in the behavioral pharmacology, biochemistry and pharmacokinetics of aniracetam provided new indications for this drug in the treatment of various CNS disorders or disease states. This article reviews these new findings and describes the effects of aniracetam in various rodent models of mental function impairment or cerebral dysfunction. Also, several metabolites of aniracetam have been reported to affect learning and memory in animals. It is, therefore, conceivable that major metabolites of aniracetam contribute to its pharmacological effects. The animal models, used in pharmacological evaluation of aniracetam included models of hypoattention, hypovigilance-arousal, impulsiveness, hyperactivity, fear and anxiety, depression, impaired rapid-eye movement sleep, disturbed temporal regulation, behavioral performance, and bladder hyperactivity. These are models of clinical disorders or symptoms that may include personality disorders, anxiety, depression, posttraumatic stress disorder, attentiondeficit/hyperactivity disorder, autism, negative symptoms of schizophrenia, and sleep disorders. At present, there is no convincing evidence that promising effects of aniracetam in the animal models will guarantee its clinical efficacy. It is conceivable, however, that clinical trials will demonstrate beneficial effects of aniracetam in the above listed disease states. New findings regarding the mechanism of action of aniracetam, its central target sites, and its effects on signal transduction are also discussed in this review article. 70

show abstract

Recovery of Diminished Mealtime-Associated Anticipatory Behavior by Aniracetam in Aged Rats

Cited by 11 publications

References 32 publications

Cognitive Aging in Zebrafish

Cognitive Aging in Zebrafish

Circadian Rhythm and Food/Nutrition

Aniracetam: Its Novel Therapeutic Potential in Cerebral Dysfunctional Disorders Based on Recent Pharmacological Discoveries

Contact Info

Product

Resources

About